[1] Liang XF, Bi SL, Yang WZ, Yang WZ, Wang LD, Cui G, et al. Evaluation of the impact of Hepatitis B vaccination among children born during 1992−2005 in China. J Infect Dis 2009;200(1):39 − 47. http://dx.doi.org/10.1086/599332CrossRef
[2] Wang FZ, Sun XJ, Wang F, Zheng H, Jia ZY, Zhang GM, et al. Changing epidemiology of Hepatitis A in China: evidence from three national serological surveys and the National Notifiable Disease Reporting System. Hepatology 2020. http://dx.doi.org/10.1002/hep.31429.http://dx.doi.org/10.1002/hep.31429
[3] Cui FQ, Shen LP, Li L, Wang HQ, Wang FZ, Bi SL, et al. Prevention of chronic Hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis 2017;23(5):765 − 72. http://dx.doi.org/10.3201/eid2305.161477CrossRef
[4] Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376(9744):895 − 902. http://dx.doi.org/10.1016/S0140-6736(10)61030-6CrossRef
[5] Liu XN, Yan H, Wang DL. The evaluation of pSafe Motherhoodq program on maternal care utilization in rural western China: a difference in difference approach. BMC Public Health 2010;10:566. http://dx.doi.org/10.1186/1471-2458-10-566CrossRef
[6] World Health Organization. China eliminates maternal and neonatal tetanus. https://www.who.int/westernpacific/news/detail/30-11-2012-china-eliminates-maternal-and-neonatal-tetanus. [2020-07-19].https://www.who.int/westernpacific/news/detail/30-11-2012-china-eliminates-maternal-and-neonatal-tetanus
[7] Nayagam S, Chan PL, Zhao K, Sicuri E, Wang XC, Jia JD, et al. Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. Clin Infect Dis 2020; ciaa134. https://doi.org/10.1093/cid/ciaa134.https://doi.org/10.1093/cid/ciaa134
[8] World Health Organization. Hepatitis E vaccine: WHO position paper, May 2015. Wkly Epidemiol Rec 2015;90(18):185−200. https://www.who.int/wer/2015/wer9018/en/.https://www.who.int/wer/2015/wer9018/en/
[9] Li X, Dumolard L, Patel M, Gacic-Dobo M, Hennessey K. Implementation of hepatitis B birth dose vaccination – worldwide, 2016. Wkly Epidemiol Rec 2018;93(7):61-72. https://apps.who.int/iris/bitstream/handle/10665/260207/WER9307.pdf;sequence=1.https://apps.who.int/iris/bitstream/handle/10665/260207/WER9307.pdf;sequence=1
[10] World Health Organization. List of prequalified vaccines. https://extranet.who.int/gavi/PQ_Web/. [2020-07-20].https://extranet.who.int/gavi/PQ_Web/
[11] World Health Organization. Global Health Sector strategy on viral hepatitis 2016-2021. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;sequence=1. [2020-07-19].https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;sequence=1
[12] Gavi. Vaccine investment strategy. https://www.gavi.org/our-alliance/strategy/vaccine-investment-strategy. [2020-07-19].https://www.gavi.org/our-alliance/strategy/vaccine-investment-strategy